Altimmune Inc ALT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALT is a good fit for your portfolio.
News
-
Thinking about buying stock in Ocugen, Ceragon Networks, Gannett, Altimmune, or Nio?
-
Thinking about buying stock in SoundHound AI, Intuitive Machines, Iovance Biotherapeutics, Silence Therapeutics, or Altimmune?
-
ROSEN, A LONGSTANDING LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALT
-
Thinking about buying stock in Intuitive Machines, SoundHound AI, Interactive Strength, Altimmune, or NanoVibronix?
-
Altimmune, Inc. (ALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALT
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
Trading Information
- Previous Close Price
- $7.57
- Day Range
- $6.99–7.57
- 52-Week Range
- $2.10–14.82
- Bid/Ask
- $7.08 / $7.10
- Market Cap
- $501.94 Mil
- Volume/Avg
- 1.4 Mil / 4.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 946.25
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company’s pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 59
- Website
- https://www.altimmune.com
Comparables
Valuation
|
Metric
|
ALT
|
MRNS
|
ICVX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.76 | 4.72 | 3.30 |
Price/Sales | 946.25 | 2.51 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ALT
MRNS
ICVX
Financial Strength
|
Metric
|
ALT
|
MRNS
|
ICVX
|
|---|---|---|---|
Quick Ratio | 16.69 | 3.79 | 17.59 |
Current Ratio | 17.26 | 4.07 | 18.06 |
Interest Coverage | −2,736.09 | −7.94 | — |
Quick Ratio
ALT
MRNS
ICVX
Profitability
|
Metric
|
ALT
|
MRNS
|
ICVX
|
|---|---|---|---|
Return on Assets (Normalized) | −34.33% | −59.45% | −29.30% |
Return on Equity (Normalized) | −37.88% | −195.80% | −31.87% |
Return on Invested Capital (Normalized) | −41.89% | −84.00% | −34.69% |
Return on Assets
ALT
MRNS
ICVX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pjmtbqgmq | Jckg | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wspvwsv | Zrhvw | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pzztdfdp | Vmkhfk | $99.6 Bil | |
MRNA
| Moderna Inc | Qgzlwkbm | Fhl | $38.8 Bil | |
ARGX
| argenx SE ADR | Wyvnscx | Fjxrn | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Rfgvbgyb | Wlsz | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qmlkprq | Snqykt | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Tfqmgkjz | Rxwqmp | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qldmlhxtsk | Wzmnwkm | $12.4 Bil | |
INCY
| Incyte Corp | Ywbtgyjn | Crffmp | $11.9 Bil |